Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S258100, C514S307000, C514S394000, C544S256000, C546S118000, C546S144000, C548S304400
Reexamination Certificate
active
10532271
ABSTRACT:
Compounds represented by the formula (I), where R1, R2, R3, R4, R5, and Q are as defined herein, exhibit activity against infectious pathogens
REFERENCES:
patent: 3622574 (1971-11-01), Wright et al.
patent: 4738980 (1988-04-01), Arcamone et al.
patent: 4766142 (1988-08-01), Arcamone et al.
patent: 4800211 (1989-01-01), Tischler et al.
patent: 4912199 (1990-03-01), Lown et al.
patent: 5017599 (1991-05-01), Lazzari et al.
patent: 5049579 (1991-09-01), Lazzari et al.
patent: 5310752 (1994-05-01), Lazzari et al.
patent: 5350748 (1994-09-01), Boschelli et al.
patent: 5395849 (1995-03-01), Wittman et al.
patent: 5472976 (1995-12-01), Animati et al.
patent: 5502068 (1996-03-01), Lown et al.
patent: 5545640 (1996-08-01), Beaulieu et al.
patent: 5616606 (1997-04-01), Lown et al.
patent: 5670534 (1997-09-01), Animati et al.
patent: 5698674 (1997-12-01), Bruice et al.
patent: 5753629 (1998-05-01), Beria et al.
patent: 5801155 (1998-09-01), Kutyavin et al.
patent: 5808087 (1998-09-01), Matsunaga et al.
patent: 5821258 (1998-10-01), Matsunaga
patent: 5844110 (1998-12-01), Gold
patent: 5852011 (1998-12-01), Matsunaga et al.
patent: 5998140 (1999-12-01), Dervan et al.
patent: 6090947 (2000-07-01), Dervan et al.
patent: 6143901 (2000-11-01), Dervan
patent: 6153642 (2000-11-01), Cozzi et al.
patent: 6172104 (2001-01-01), Tidwell et al.
patent: 6458768 (2002-10-01), Cozzi et al.
patent: 6555693 (2003-04-01), Ge et al.
patent: 6566393 (2003-05-01), Lee et al.
patent: 6586561 (2003-07-01), Litt et al.
patent: 6716866 (2004-04-01), McMinn et al.
patent: 6777425 (2004-08-01), Bürli et al.
patent: 6825228 (2004-11-01), Bürli et al.
patent: 2003/0199516 (2003-10-01), Moser et al.
patent: 2003/0211508 (2003-11-01), Ge et al.
patent: 2003/0236198 (2003-12-01), Bürli et al.
patent: 2005/0004042 (2005-01-01), Hu et al.
patent: 199 20 936 (2000-11-01), None
patent: 2 310 207 (1996-02-01), None
patent: 08-027146 (1996-10-01), None
patent: 08-269008 (1996-10-01), None
patent: 11-171886 (1999-06-01), None
patent: 11-189594 (1999-07-01), None
patent: WO92/13838 (1992-08-01), None
patent: WO93/13739 (1993-07-01), None
patent: WO94/20463 (1994-09-01), None
patent: WO95/24419 (1995-09-01), None
patent: WO96/26950 (1996-09-01), None
patent: WO97/03957 (1997-02-01), None
patent: WO97/25351 (1997-07-01), None
patent: WO97/28123 (1997-08-01), None
patent: WO98/21202 (1998-05-01), None
patent: WO98/35702 (1998-08-01), None
patent: WO98/37066 (1998-08-01), None
patent: WO98/37067 (1998-08-01), None
patent: WO98/37087 (1998-08-01), None
patent: WO98/43663 (1998-10-01), None
patent: WO98/45284 (1998-10-01), None
patent: WO98/49142 (1998-11-01), None
patent: WO98/50582 (1998-11-01), None
patent: WO98/52614 (1998-11-01), None
patent: WO99/00364 (1999-01-01), None
patent: WO99/25686 (1999-05-01), None
patent: WO99/27939 (1999-06-01), None
patent: WO99/41367 (1999-08-01), None
patent: WO99/50265 (1999-10-01), None
patent: WO99/50266 (1999-10-01), None
patent: WO99/62890 (1999-12-01), None
patent: WO99/64413 (1999-12-01), None
patent: WO 00/06541 (2000-02-01), None
patent: WO 00/06542 (2000-02-01), None
patent: WO 00/15209 (2000-03-01), None
patent: WO 00/15773 (2000-03-01), None
patent: WO 00/40605 (2000-07-01), None
patent: WO 00/69432 (2000-11-01), None
patent: WO 01/10439 (2001-02-01), None
patent: WO 01/19792 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/74898 (2001-10-01), None
patent: WO 01/96313 (2001-12-01), None
patent: WO 02/00650 (2002-01-01), None
patent: WO 02/088119 (2002-11-01), None
patent: WO 02/101073 (2002-12-01), None
patent: WO 2004/012736 (2004-02-01), None
Arcamone, F. et al., “Synthesis, DNA binding and antiviral activity of distamycin analogues containing different heterocyclic moieties.”Anti-Cancer Drug Design, 1:235-244 (1986).
Bailly, C. and J.B. Chaires, “Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues.”Bioconj. Chem., 9(5):513-538 (1998).
Baird, E.E. and P.B. Dervan, “Solid phase synthesis of polyamides containing imidazole and pyrrole amino acids.”J. Am. Chem. Soc., 118:6141-46 (1996).
Baraldi et al., “Synthesis of 3-Substituted-7-alkoxy-5H-pyrazolo [4, 3-d],2,3-triazin-4(3H)-ones”Synthesis, pp. 1437-1440, (1994), XP002208604.
Baraldi, P.G. et al., “Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.”J. Med. Chem., 43:2675-2684 (2000).
Berge, S.M., et al, “Pharmaceutical Salts”,J. Pharm. Sci., 66:1-19 (1977).
Bilder G. et al., “Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A.”Circulation, 99(25):3292-99 (1999).
Boger, D.L. et al., “A simple, high-resolution method for establishing DNA binding affinity and sequence selectivity.”J. Am. Chem. Soc., 123:5878-91 (2001).
Boger, D.L. et al., “Total synthesis of distamycin A and 2640 analogues: A solution-phase combinatorial approach to the discovery of new bioactive DNA binding agents and development of a rapid high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity.”J. Am. Chem. Soc., 122:6382-94 (2000).
Bremer, R.E. et al., “Recognition of the DNA minor groove by pyrrole-imidazole polyamides: comparison of desmethyl-and n-methylpyroole.”Bioorg. Med. Chem., 8:1947-55 (2000).
Bruice, Thomas C. et al., “Rational design of substituted tripyrrole peptides that complex with DNA by both slelective minor-groove binding and electrostatic interaction with the phosphate backbone.”Proc. Natl. Acad. Sci. USA, 89:1700-04 (1992).
Chiarino, D. et al., “Synthesis of new isoxazole aminoalcohols.”J. Heterocyclic Chem., 25(1):337-342 (1988).
Choudhury, G.G. et al., “Involvement of PKC-alpha in PDGF-mediated mitogenic signaling in human mesangial cells.”Am. J. Physiol., 265(5 Pt 2):F634-42 (1993).
Corallini, A. et al. “Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein.”AIDS Res. Hum. Retroviruses, 4(17):1561-71 (1998).
Dyatkina, N.B. et al., “Minor grove DNA binders as antimicrobial agents. 1. Pyrrole tetraamides are potent antibacterials against vancomycin resistant Enterococci [corrected] and methicillin resistantStaphyloccus aureus.” J. Med. Chem.; 45(4):805-17 (2002).
Ellervik, U. et al., “Hydroxybenzamide/pyrrole pair distinguishes T·A from A·T base pairs in the minor groove of DNA”J. Am. Chem. Soc.122(39):9354-60 (2000).
El-Naggar, A.M. et al., “Synthesis of some 2-thenoyl-, 5-bromo-2-thenoyl- and 5-nitro-2-thenoylamino acid derivatives and their antimicrobial activity.”J. Indian Chem. Soc., LIX:783-786 (1982).
Fenwick et al., “Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K.”Bioorg. Med. Chem. Lett., 11:195-98 (2001).
Floreancig, P.E. et al., “Recognition of the minor groove of DNA by hairpin polyamides containing alpha-substituted-beta-amino acids.”J. Am. Chem. Soc., 122:6342-50 (2000).
Goodsell D. and R.E. Dickerson, “Isohelical analysis of DNA groove-binding drugs.”J. Med. Chem., 29(5):727-33 (1986).
Gougerot-Pocidalo, M.A. et al. “Mechanisms by which oxidative injury inhibits the proliferative response of human lymphocytes to PHA. Effect of the thiol compound 2-mercaptoethanol.”Immunology; 64(2):281-8 (1988).
Gupta et al., “Hybrid molecules containing propargylic sulfones and DNA minor groove-binding lexitropsins: synthesis, sequence specificity of reaction with DNA and biological evaluation.”Gene, 149:81-90 (1994).
Handler, J.A. et al., “Mitogenic signaling by epidermal growth factor (EGF), but not platelet-derived growth factor, requires arachidonic acid metabolism in BALB/c 3T3 cells. Modulation of EGF-dependent c-myc expression by pro
Burli Roland W.
Jiang Chun
Jones Peter
McMinn Dustin L.
Davis Zinna N.
Genesoft Pharmaceuticals, Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Anti-infective biaryl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-infective biaryl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-infective biaryl compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796439